Aktis Oncology IPO Raises $318 Million, Vida Ventures Congratulates on Successful Entry into Public Markets.

Vida Ventures congratulates Aktis Oncology on its entry into the public markets, raising $318 million in its initial public offering. Vida has supported Aktis since its Series A, co-leading the investment and serving on the board. Aktis' pipeline includes alpha-emitting radiopharmaceuticals for solid tumor treatment, with a recent anchor investment by Eli Lilly and Company. Vida is the second-largest shareholder in the company leading up to the IPO.